Price T Rowe Associates Inc Chemo Centryx, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $229,060 - $535,197	10,332 Added 3.33%	320,461 $16.6 Million
Q2 2022 Aug 15, 2022	SELL	$15.36 - $27.51 $852,556 - $1.53 Million	-55,505 Reduced 15.18%	310,129 $7.69 Million
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $39,751 - $69,985	-1,789 Reduced 0.49%	365,634 $9.17 Million
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $169,077 - $372,559	-9,199 Reduced 2.44%	367,423 $13.4 Million
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $899,877 - $1.35 Million	-68,276 Reduced 15.35%	376,622 $6.44 Million
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $82,684 - $438,687	8,622 Added 1.98%	444,898 $5.96 Million
Q1 2021 May 17, 2021	BUY	$49.53 - $68.4 $1.64 Million - $2.27 Million	33,148 Added 8.22%	436,276 $22.4 Million
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $19 Million - $26.3 Million	403,128 New	403,128 $25 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.